| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047300519 |
| P356 | DOI | 10.1186/1750-1326-7-1 |
| P8608 | Fatcat ID | release_2tadq2yyizemliwuotim6adbt4 |
| P932 | PMC publication ID | 3277480 |
| P698 | PubMed publication ID | 22222029 |
| P5875 | ResearchGate publication ID | 221726440 |
| P2093 | author name string | Todd E Golde | |
| Domenico Pratico | |||
| Phillip F Giannopoulos | |||
| Jin Chu | |||
| Carolina Ceballos-Diaz | |||
| P2860 | cites work | Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 |
| BRI2 (ITM2b) inhibits Abeta deposition in vivo | Q24319041 | ||
| Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet | Q24644293 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease | Q30444790 | ||
| Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease | Q30497574 | ||
| PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. | Q34169736 | ||
| Transcriptional regulation of PEN-2, a key component of the gamma-secretase complex, by CREB | Q34353695 | ||
| Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability | Q34463247 | ||
| 5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo | Q34636148 | ||
| Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase | Q34805615 | ||
| 5-Lipoxygenase: regulation of expression and enzyme activity | Q36852065 | ||
| Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. | Q36974939 | ||
| 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease | Q37232572 | ||
| Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase | Q39689586 | ||
| A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism | Q40079113 | ||
| Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain | Q40329324 | ||
| Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. | Q42247303 | ||
| 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease | Q43670979 | ||
| Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. | Q43913392 | ||
| Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice | Q46964616 | ||
| The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. | Q48438144 | ||
| Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. | Q52012764 | ||
| Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. | Q52173404 | ||
| Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling | Q70790631 | ||
| P433 | issue | 1 | |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2012-01-05 | |
| P1433 | published in | Molecular Neurodegeneration | Q15817329 |
| P1476 | title | Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice | |
| P478 | volume | 7 |
| Q36299503 | 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease |
| Q36680982 | 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. |
| Q47438369 | Brain 5-lipoxygenase over-expression worsens memory, synaptic integrity, and tau pathology in the P301S mice |
| Q41863415 | Commentary: Advancement of Knowledge of Brucella Over the Past 50 Years |
| Q38728679 | Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases. |
| Q38784992 | Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability |
| Q57048505 | Downregulation of autophagy by 12/15Lipoxygenase worsens the phenotype of an Alzheimer's disease mouse model with plaques, tangles, and memory impairments |
| Q35991969 | Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus |
| Q33647503 | FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo . |
| Q91410845 | Full recovery of the Alzheimer's disease phenotype by gain of function of vacuolar protein sorting 35 |
| Q37184747 | GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome |
| Q36524290 | Gene Therapy Models of Alzheimer's Disease and Other Dementias |
| Q33844923 | Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease |
| Q38044434 | Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models |
| Q36181709 | Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model |
| Q37678676 | Novel lipid signaling pathways in Alzheimer's disease pathogenesis |
| Q47412565 | Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy |
| Q35929097 | Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy |
| Q34650215 | Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein |
| Q46337796 | Protective effect of pranlukast on Aβ₁₋₄₂-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1. |
| Q34477953 | RETRACTED: Gene expression profiling analysis of the putamen for the investigation of compensatory mechanisms in Parkinson's disease |
| Q35745694 | Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence |
| Q58027500 | Rodent models for Alzheimer disease |
| Q47369903 | Tactile stimulation during different developmental periods modifies hippocampal BDNF and GR, affecting memory and behavior in adult rats. |
| Q37337281 | The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo |
| Q38785505 | The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target |
| Q26999358 | The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype |
| Q38671719 | The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. |
| Q47284015 | The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy |
| Q37053817 | The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence |
| Q91754836 | VPS35 regulates tau phosphorylation and neuropathology in tauopathy |
Search more.